Hypertension Canada (formerly the Canadian Hypertension Education Program, CHEP) has been publishing evidence-based guidelines for the diagnosis and management of hypertension since 1999. 1 The 2017 guidelines, 2 released earlier this year, denote the 19th annual synthesis and update of evidence to date in hypertension. These guidelines, together with knowledge translation programs for health care professionals, 3 have helped to improve the levels of detection and management of hypertension in Canada and reduced associated cardiovascular mortality. 4, 5 Indeed, the proportion of patients with controlled blood pressure in Canada has significantly increased from 13.2% in 1992 5 to 68.1% in 2012-2013. 4 A multidisciplinary expert panel is responsible for the synthesis and dissemination of Hypertension Canada's guidelines. To date, the panel has consisted of physicians, nurses and pharmacists, among other disciplines.
Pharmacists are well positioned to manage hypertension, as they see patients with chronic conditions more frequently than any other health care professional. 6 Furthermore, the growing body of evidence supporting pharmacist interventions is indisputable. [7] [8] [9] [10] [11] [12] [13] As such, Hypertension Canada has recognized pharmacists' expanded scope of practice as one approach to improve the detection and management of hypertension in Canada.
The Canadian Pharmacists Journal has regularly published pharmacist-specific hypertension guidelines, with the most recent full set of guidelines published in 2011 14 and regular updates thereafter. This article highlights updates that have been integrated into the current 2017 Hypertension Canada guidelines, in addition to elements that the authors feel are still important from previous publications. Readers requiring Hypertension Canada's full guidelines are encouraged to refer to the Canadian Journal of Cardiology, 2 www.hypertension.ca or previous versions of pharmacist-specific publications in the Canadian Pharmacists Journal.
What's new
The 2017 Hypertension Canada guidelines present 6 changes relevant to pharmacists (Box 1).
Indications for drug therapy in adults with hypertension
Antihypertensive therapy should be provided to all patients without macrovascular target
The previous guideline recommendations for alternate blood pressure targets in the frail and elderly have been removed.
PRaCtiCe guideLiNes
organ damage, such as myocardial infarction and stroke, or other cardiovascular risk factors (e.g., dyslipidemia, smoking, diabetes mellitus, sedentary lifestyle and obesity) with average diastolic blood pressure (DBP) readings of ≥100 mmHg (Grade A) and/or average systolic blood pressure (SBP) readings of ≥160 mmHg (Grade A). 15 In addition, antihypertensive therapy should be strongly considered for all patients with macrovascular target organ damage or other independent cardiovascular risk factors with average DBP readings of ≥90 mmHg (Grade A) and/or average SBP readings of ≥140 mmHg (Grade B for 140-160 mmHg, Grade A for >160 mmHg). All patients should be treated to achieve a SBP target of <140 mmHg (Grade C) and/or a DBP target of <90 mmHg (Grade A); however, caution should be used in elderly patients experiencing orthostasis.
A post hoc analysis of the HYVET trial 16 and a subgroup analysis of the SPRINT trial 17, 18 
Choice of therapy for adults with hypertension without compelling indications for specific agents
This preference is guided by evidence supporting the use of long-acting diuretics to reduce blood pressure and cardiovascular events. 20 Practice guidelines with extended-release hydrochlorothiazide and thiazide-like diuretics compared to conventional hydrochlorothiazide.
Combination antihypertensive therapy is associated with a reduced likelihood of cardiovascular events compared to monotherapy. 23, 30 Furthermore, SPCs have been shown to be more effective at reducing blood pressure compared to monotherapy. A meta-analysis of 42 randomized clinical trials demonstrated that the combination of 2 drugs of different classes resulted in a 5-fold greater reduction in systolic blood pressure compared to doubling the dose of 1 drug. 24 These findings are supported by evidence from the STITCH study, 25 where a larger blood pressure reduction (-5.2/-2.2) was observed in individuals receiving initial fixed-dose combination therapy of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) and diuretic, compared to monotherapy with uptitration at 6 months. 25 Moreover, a greater percentage of individuals reached their target blood pressure (64.7% vs 52.7%, p = 0.03).
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A meta-analysis conducted by Sherrill and colleagues 28 found that the use of SPCs was associated with improved adherence rates and lower health care costs compared to the use of the individual components. Furthermore, another meta-analysis conducted by Law and colleages 29 found that fixed-dose antihypertensive combinations were associated with a lower incidence of adverse events and improved efficacy. When choosing an SPC, it is recommended to use an ACE inhibitor combined with a calcium channel blocker (CCB) (Grade A), an ARB combined with a CCB (Grade B) or an ACE or ARB combined with a diuretic (Grade B). This recommendation is supported by the ACCOM-PLISH trial, 26 which randomized high-risk adults to either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The composite of cardiovascular death and major adverse cardiovascular events was significantly reduced with benazepril plus amlodipine compared to benazepril plus hydrochlorothiazide (HR, 0.80; 95% CI, 0.72-0.90). The HOPE-3 27 and STITCH 25 trials support the use of an ACE inhibitor or ARB combined with a diuretic. While the HOPE-3 trial reported no significant difference in the 2 coprimary outcomes for individuals with an intermediate risk of cardiovascular events with candesartan-hydrochlorothiazide vs placebo overall, a significant reduction in the coprimary endpoints was demonstrated in those with higher blood pressure or hypertension (SBP >143.5 mmHg).
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Treatment of hypertension in association with ischemic heart disease
This recommendation is supported by post hoc analyses of several studies showing that in patients with CAD, reducing blood pressure below a specific threshold was associated with an increased risk of coronary events. [31] [32] [33] [34] Individuals with left ventricular hypertrophy may be at greatest risk due to increased myocardial demand and decreased coronary perfusion during diastole. Indeed, an association between reduced coronary blood flow and increased left ventricular mass was noted in patients with CAD and was most pronounced at DBP <70 mmHg. 35 These findings are in line with a meta-analysis conducted by Rabkin. 36 Even so, the 2017 guidelines 2 still strongly recommend antihypertensive therapy for most patients who can tolerate blood pressure reduction, especially those with moderate or severe hypertension, due to the benefits of blood pressure reduction in these high-risk individuals, which likely outweigh the associated risks.
Treatment of hypertension in association with hemorrhagic stroke
Single-pill combinations (SPCs) are recommended as an initial treatment option (Grade A) based on evidence supporting their effectiveness in reducing blood pressure and cardiovascular events. [23] [24] [25] [26] [27] In addition, SPCs have been shown to improve adherence and reduce the incidence of adverse events. 28, 29 When treating SBP to target in patients with established coronary artery disease (CAD) (especially in those with isolated systolic hypertension), exercise caution when DBP is ≤60 mmHg due to concerns with exacerbating myocardial ischemia, especially for patients with left ventricular hypertrophy (Grade D).
In patients in the hyperacute phase (first 24 hours) of intracerebral hemorrhage, avoid SBP lowering to <140 mmHg due to a lack of benefit (relative to a target of <180 mmHg) and the potential for harm (Grade A).
PRaCtiCe guideLiNes
Trial evidence demonstrated no benefit and potential harm with SBP targets of <140 mmHg in the acute phase of intracerebral hemorrhage. 37, 38 INTERACT-2 randomized 2839 patients who had a spontaneous intracerebral hemorrhage within 6 hours of onset to a target SBP of either <140 mmHg or <180 mmHg (applied within the first hour of spontaneous intracerebral hemorrhage presentation). 37 There was no statistical difference in the primary outcome of death or stroke-related disability at 90 days when comparing the 2 SBP targets (odds ratio [OR], 0.87; 95% CI, 0.75-1.01). These findings are consistent with the ATACH-2 trial, 38 where 1000 patients presenting with spontaneous intracerebral hemorrhage were randomized to SBP targets of 110 to 139 mmHg or 140 to 179 mmHg. Treatment was initiated within 4.5 hours after symptom onset and continued for the next 24 hours. 38 No difference in the primary outcome of death or stroke-related disability was observed between the 2 arms; however, there was a trend toward greater adverse events in the lower SBP arm.
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Resistant hypertension
Resistant hypertension affects 10% to 20% of patients treated for high blood pressure and is associated with increased cardiovascular risk compared to other forms of hypertension. 40 As such, no specific guideline recommendations were generated on the basis of its results. Figure 1 illustrates the recommended diagnostic algorithm for hypertension. After an initial finding of in-office elevated blood pressure, it is recommended to use out-of-office blood pressure measurements to confirm the initial diagnosis of hypertension, as it better predicts cardiovascular outcomes compared to in-office measurements. 43 Moreover, out-of-office blood pressure measurements can identify both white coat and masked hypertension. 43 Ambulatory blood pressure monitoring is the preferred out-of-office measurement (Grade D) as it provides a greater number of readings, as well as information regarding nocturnal blood pressure, and is considered a strong predictor of cardiovascular events. 44 When using this method, patients can be diagnosed with hypertension if the mean ambulatory 24-hour blood pressure is ≥130/80 mmHg or the mean awake ambulatory blood pressure is ≥135/85 mmHg (Grade C). If ambulatory blood pressure monitoring is not available, cannot be tolerated or patient preference precludes use, home blood pressure monitoring can be used (Grade D). A diagnosis of hypertension can be made if the mean home blood pressure is ≥135/85 mmHg following duplicate measures, morning and evening, for 7 days, with the first day's values excluded from the overall mean calculation (Grade C). Automated office blood pressure (AOBP) is the preferred method for in-office measurements (Grade D), with a mean blood pressure of ≥135/85 mmHg considered elevated (Grade D).
What is still important
If the patients' in-office blood pressure is elevated (AOBP ≥135/85 mmHg) and the mean awake home blood pressure is <135/85 mmHg The 2017 guidelines recognize resistant hypertension as an area of concern; however, due to a lack of event-related outcomes from the PATHWAY-2 trial, 39 no specific guideline recommendations were made.
or the mean 24-hour ambulatory blood pressure is <130/80 mmHg, then a diagnosis of white coat hypertension can be made (Grade D). Antihypertensive therapy should not be initiated under these circumstances (Grade C) due to a lack of benefit and increased risk of adverse events.
Assessment and management of overall cardiovascular risk and vascular protection
High blood pressure represents a major risk factor for premature death and disability. 45, 46 Furthermore, 80% of patients with hypertension have at least 1 additional risk factor for cardiovascular disease, 47 further increasing the likelihood of an event. As such, overall cardiovascular risk should be assessed in all patients with hypertension. Cardiovascular risk engines can be used to more accurately predict the patient's overall cardiovascular risk (Grade A) and improve the efficiency of antihypertensive therapy (Grade D). Pharmacists may consider counselling patients about their overall cardiovascular risk and consider using comparative risk analogies, such as "cardiovascular age, " "heart age" or "vascular age" (Grade B) to help advise patients about their risk. This approach improves both the If AOBP is used, use the mean calculated and displayed by the device. If non-AOBP is used, take at least 3 readings, discard the first, and calculate the mean of the remaining measurements. A history and physical exam should be performed and diagnostic tests ordered. 2 AOBP is performed with the patient unattended in a private area. Non-AOBP is performed using an electronic upper arm device with the provider in the room. 3 Diagnostic thresholds for AOBP, ABPM and home BP in patients with diabetes have yet to be established (and might be lower than 130/80 mmHg). 4 Serial office measurements over 3 to 5 visits can be used if ABPM or home measurement is not available. 5 For a home BP series, 2 readings are taken each morning and evening for 7 days (28 total). Discard the first day readings and average the last 6 days. PRaCtiCe guideLiNes effectiveness of risk factor modification as well as the patient's perception of risk. [48] [49] [50] [51] [52] The R X EACH study randomized 723 patients to receive pharmacist intervention (including prescribing) or usual care. 13 Pharmacist intervention comprised individualized cardiovascular risk assessment and education regarding this risk. 13 Compared to usual care, greater reductions in cardiovascular risk (21%, p < 0.001) and blood pressure (-9.37/-2.92 mmHg, p < 0.001) were observed in the pharmacist intervention group at 3 months. 13 These findings highlight the importance of overall cardiovascular risk assessment in this patient population. Statin therapy is recommended in hypertensive patients who have ≥3 cardiovascular risk factors (Grade A, in patients >40 years) or established atherosclerotic disease (Grade A, irrespective of age). Risk factors include the following: Low-dose acetylsalicylic acid (ASA) therapy may also be considered for patients with hypertension who are 50 years or older (Grade B); however, caution should be used in patients whose blood pressure remains uncontrolled (Grade C).
Pharmacists should assess tobacco use regularly and advise on tobacco cessation in all patients (Grade C). Tobacco use represents a significant contributor to elevated blood pressure and cardiovascular risk. 53 As such, tobacco cessation is crucial to reducing vascular risk. The pharmacists' role in smoking cessation is supported by a meta-analysis conducted by Saba and colleagues. 54 Five randomized controlled trials with a total of 1426 smokers were included in the analysis. Pharmacists should ensure patient risk assessment is consistent with the above criteria before initiating intensive treatment. In addition, patients should consent to receiving intensive treatment that includes multiple antihypertensive medications and an increased frequency of follow-up visits. A careful risk-benefit analysis should be performed due to the propensity for adverse events with intensive blood pressure management. Moreover, such treatment should be avoided in certain high-risk groups (Grade B) due to a lack of supporting evidence. These highrisk groups include the following:
• Patients with heart failure (ejection fraction <35%) or recent myocardial infarction (within the past 3 months) • An indication for, but not currently receiving, a beta-blocker 
Adherence
Patient nonadherence to antihypertensive therapy is common and has a significant impact on blood pressure control and cardiovascular complications. [57] [58] [59] Early discontinuation of treatment is one of the most common causes of nonadherence. 60 One systematic review and meta-analysis found that 45% of patients with hypertension were not taking their antihypertensive therapy, and a higher proportion (83.7%) of patients with uncontrolled hypertension were nonadherent to therapy. 57 Thus, evaluating and assisting patients with adherence is a crucial step in the management of hypertension. Health care providers can improve patient adherence using a comprehensive approach addressing factors relating to patients, medications and themselves. 58, 59 Moreover, pharmacist intervention and management of blood pressure has been shown to improve adherence rates. 
Evidence for pharmacist-led interventions
The pharmacists' role in chronic disease management is becoming increasingly prominent as a result of an expanded scope of practice and the growing strain on the health care system. Research has demonstrated the benefits of pharmacist-led interventions for hypertension management. [7] [8] [9] [10] [11] [12] Indeed, Hypertension Canada is exceedingly supportive of the pharmacist's expanded role to improve hypertension detection and management, as well as reduce the risk of cardiovascular events. A systematic review and meta-analysis of 39 randomized controlled trials comprising over 14,000 patients showed that pharmacists' interventions-namely, patient education, recommendations to physicians and medication management-resulted in greater reductions of both SBP (−7.6 mmHg; 95% CI, -9 to −6.3) and DBP (−3.9 mmHg; 95% CI, −5.1 to −2.8) compared with usual care. 9 Interestingly, the most pronounced effect on blood pressure reduction was seen when the pharmacist led the intervention, resulting in a SBP reduction of -8.5 mmHg and a DBP reduction of -4.6 mmHg. Results from the R x ACTION trial demonstrated an even greater effect on blood pressure reduction when pharmacist interventions included independent prescribing for hypertension (mean SBP reduction 18.3 mmHg, adjusted difference 6.6 mmHg). 10 In addition, patients in the pharmacist prescribing arm were 2.3 times more likely to achieve target blood pressures. A recent economic analysis evaluating the costeffectiveness of pharmacist care for managing hypertension found that pharmacist-led interventions were economically dominant, being more effective (i.e., reduced blood pressure) and with a lifetime cost savings of $6364. 
